Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYSTIQUE: Omalizumab Dose-Ranging in CIU
NCT00866788Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2009
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Genentech. Started Mar 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT00866788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866788.